Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 5, 2017, Pages 1415-1420

  Lenhard, Justin R ^a,b   Thamlikitkul, Visanu ^c   Silveira, Fernanda P ^d   Garonzik, Samira M ^a   Tao, Xun ^e   Forrest, Alan ^a,f   Shin, Beom Soo ^g   Kaye, Keith S ^h   Bulitta, Jürgen B ^e   Nation, Roger L ⁱ   Li, Jian ⁱ   Tsuji, Brian T ^a,j  

^a UNIVERSITY AT BUFFALO   (United States)

^b CALIFORNIA NORTHSTATE UNIVERSITY   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f UNC Hamner Institute for Drug Safety Sciences   (United States)

^g Sungkyunkwan University   (South Korea)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

ⁱ MONASH UNIVERSITY   (Australia)

^j VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; COLISTIN; MEROPENEM; POLYMYXIN B; SULTAMICILLIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; THIENAMYCIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL GROWTH; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLONAL VARIATION; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONCENTRATION AT STEADY-STATE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG DISPOSITION; DRUG DOSE ESCALATION; HALF LIFE TIME; HOLLOW FIBRE INFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; YOUNG ADULT; CASE REPORT; DRUG EFFECTS; DRUG POTENTIATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADULT; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYMYXIN B; THIENAMYCINS;

EID: 85020125949     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx002     Document Type: Article

References (16)

1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538-82
2. Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. FrontMicrobiol 2014; 5: 643
3. Liu YY, Wang Y, Walsh TR et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 2016; 16: 161-8
4. Qureshi ZA, Hittle LE, O'Hara JA et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis 2015; 60: 1295-303
5. Sandri AM, Landersdorfer CB, Jacob J et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013; 57: 524-31
6. GaronzikSM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistinmethanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55: 3284-94
7. Lenhard JR, Brown T, Rybak MJ et al. Sequential evolution of vancomycinintermediate resistance alters virulence in Staphylococcus aureus: pharmacokinetic/ pharmacodynamic targets for vancomycin exposure. Antimicrob Agents Chemother 2015; 60: 1584-91
8. Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 2008; 52: 351-2
9. Tsuji BT, Landersdorfer CB, Lenhard J et al. The paradoxical effect of polymyxinB: highdrugexposureamplifies resistance inAcinetobacter baumannii. Antimicrob Agents Chemother 2016; 60: 3913-20
10. Kaye KS, Pogue JM, Tran TB et al. Agents of last resort: polymyxin resistance. Infect Dis Clin NorthAm2016; 30: 391-414
11. Betrosian AP, Frantzeskaki F, Xanthaki A et al. High-dose ampicillinsulbactam as an alternative treatment of late-onset VAP from multidrugresistant Acinetobacter baumannii. Scand J Infect Dis 2007; 39: 38-43
12. Blaser J. In-vitromodel for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J Antimicrob Chemother 1985; 15 (Suppl A): 125-30
13. Cheah SE, Bulitta JB, Li J et al. Development and validation of a liquid chromatography-mass spectrometry assay for polymyxin B in bacterial growth media. J Pharm Biomed Anal 2014; 92: 177-82
14. Lenhard JR, Bulitta JB, Connell TD et al. High-intensitymeropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii. JAntimicrobChemother 2016; 72: 153-65
15. Nation RL, Garonzik SM, Li J et al. Updated US and European dose recommendations for intravenous colistin: how do they perform? Clin Infect Dis 2016; 62: 552-8
16. Mahamad Maifiah MH, Cheah SE, Johnson MD et al. Global metabolic analyses identify key differences in metabolite levels between polymyxinsusceptible and polymyxin-resistant Acinetobacter baumannii. Sci Rep 2016; 6: 22287